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Recently some have called for randomized controlled trials comparing RFA to hepatic resection, particularly for patients with
only a few small metastases. The objectives were to compare local recurrence and survival following RFA and hepatic resection
for colorectal liver metastases. This was a retrospective review of open RFA and hepatic resection for colorectal liver metastases
between January 1998 and May 2007. All patients who had RFA were considered to have unresectable disease. 58 patients had
hepatic resection and 43 had RFA. A 5-year survival after resection was 43% compared to 23% after RFA. For patients with solitary
lesions, a 5-year survival was 48% after resection and 15% after RFA. Sixty percent of patients suﬀered local recurrences after RFA
compared to 7% after hepatic resection. RFA is inferior to resection. The results observed in this study support the consensus that
RFA cannot be considered an equivalent procedure to hepatic resection.
Copyright © 2009 Andrew McKay et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hepatic resection is a major surgical intervention with
signiﬁcantpotentialcomplicationsrisk.Mucheﬀorthasbeen
placed on developing regional ablative techniques such as
radiofrequency ablation (RFA) [1, 2] in hopes of achieving
similar survival as with hepatic resection, but with less
morbidity. However, the outcomes following RFA have not
been ﬁrmly established. While some authors have reported
that local recurrence rates with RFA are not signiﬁcantly
diﬀerent than those with anatomic or wedge resections of
the liver [3], the current literature reports a wide range of
local recurrence rates for colorectal liver metastases treated
with RFA. These rates range from 5% [4] to as high as 39%
[5, 6]. Reports of low recurrence rates may be a function
of patient selection (i.e., small lesions) or short follow-up
in some instances, and many series have combined patients
with primary and secondary hepatic malignancies. To date,
long-term survival remains diﬃcult to interpret. In all
these studies, patients were considered to have unresectable
disease, which limits comparisons to patients undergoing
hepatic resection.
Several studies have reported favorable survival rates and
this has prompted some authors to call for randomized
controlled trials comparing RFA to hepatic resection [7–
9]. Other results have been much less optimistic [10]. An
updated report from the same center [11] showed that with
longer follow-up, the proportion of patients treated with
RFA that had recurrence at the ablation site had risen from
9% to 37%. Furthermore, the 5-year overall survival for
patients who had RFA was signiﬁcantly inferior to those
who had resection, even though patient characteristics and
the proportion of patients receiving adjuvant chemotherapy
were similar between groups.
The eﬀectiveness of RFA remains controversial, and in
the absence of randomized studies several questions remain.
Patient selection is an obvious concern and publication bias
may be present.
The hypothesis of this study is that treatment with RFA
leads to signiﬁcantly higher recurrence rates and decreased
survival compared to surgical resection. If this is conﬁrmed,
then this will provide important evidence that will be helpful
in guiding treatment decisions for patients with potentially
resectable colorectal liver metastases.2 HPB Surgery
The objectives of this study are to report the local
recurrence rates and overall survival rates following open
RFA and following hepatic resection for the treatment of
colorectal liver metastases in the Province of Manitoba.
2.MaterialsandMethods
2.1. Study Design. This was a retrospective review of the
outcomes of RFA and hepatic resection for colorectal liver
metastases. The primary outcome measures were recurrence
r a t e sa n do v e r a l ls u r v i v a l .T h es t u d yw a sa p p r o v e db yt h e
Health Research Ethics Board at the University of Manitoba.
2.2. Subjects. The study was conducted from January 1998,
the year when RFA ﬁrst became available in Manitoba,
until June 2007. All patients who underwent open RFA
and/or surgical resection for colorectal liver metastases at
either Health Sciences Centre (HSC) or St. Boniface General
Hospital (SBGH), the two University-aﬃliated teaching
hospitals in the Province, were included in the study. All
majorhepaticsurgeryintheProvincewasperformedatthese
two hospitals; thus, it was a population-based study. The
population oftheProvinceisjustover1.1millionpeopleand
the catchment area of the two hospitals is slightly larger than
that. Patients received systemic chemotherapy at CancerCare
Manitoba (CCMB), an outpatient oncology centre for the
province.
2.3. Procedure. All patients had previously underwent hep-
atic resection or RFA. All patients who had hepatic resection
ﬁrst had intraoperative ultrasound performed. In the early
years of the study period, parenchymal transection was
done with the “clamp-crush” method and with the Cavitron
Ultrasonic Surgical Aspirator (CUSA; Integra Life Sciences).
All patients who underwent RFA were considered to have
unresectable disease. Due to the retrospective nature of this
analysis, it is not possible to determine the exact reason
why patients were considered to have unresectable disease
in each case. However, in general patients were considered
to have unresectable disease because of extensive disease
that would result in an insuﬃcient liver remnant, proximity
to critical structures, prohibitive comorbidity, or patient
refusal.RFAwasperformedasanopenprocedureinallcases.
An open approach was chosen over a percutaneous approach
because of the added beneﬁt of intraoperative ultrasound to
discover unsuspected disease [12, 13], the potentially lower
recurrencewithanopentechnique[14],theabilitytoprotect
adjacent structures, and the ability to perform simultaneous
resection in select cases. RFA was done under real-time
ultrasound guidance using the RF 3000 Radiofrequency
Ablation System (Boston Scientiﬁc) with either a 3cm or
4cm probe. The RFA tract was routinely ablated as the probe
was withdrawn.
Systemic chemotherapy was administered at the discre-
tion of the medical oncologists. Towards the end of the
study period, chemotherapy was generally oﬀered to all
patients who were medically ﬁt. Towards the end of the study
period chemotherapy usually consisted of 5-ﬂuourouracil
and leucovorin in combination with either irinotecan or
oxaliplatin, but a variety of regimens were used.
Eligible patients were later identiﬁed from the Med-
ical Records Departments of both HSC and SBGH. The
hospital charts and the outpatient charts at CCMB were
then reviewed for demographic information, patient factors
includingcomorbidities,pathologicalfeaturesoftheprimary
tumors, dates of diagnoses, and the treatments received.
The characteristics of the tumors including the number,
distribution, and size of lesions were analyzed along with the
nature and extent of the operative procedures. The outpa-
tient charts were reviewed for dates and locations of disease
recurrences. The Manitoba Health Population Registry is an
administrative database belonging to Manitoba Health (the
government agency that provides health insurance for all
Manitobans). It lists up-to-date vital statistic, migration and
loss to follow-up information for all people living in the
Province of Manitoba, and was accessed in order to obtain
the most accurate survival information possible.
Postoperative morbidity was graded according to a
previously validated classiﬁcation system [15]. Mortality was
deﬁned as either 30-day mortality or in-hospital mortality
if patients died in hospital beyond 30 days. This is because
mortality from postoperative liver failure in major hepatic
surgery may occur well beyond 30 days [16], which is a
commonly used end-point.
The outcomes for patients who underwent RFA, RFA
plus hepatic resection, and hepatic resection were reported.
The analysis focused mainly on comparing those who
underwent hepatic resection to those who underwent RFA.
Although, it was hypothesized that the limiting factor in
terms of survival and recurrence in those who underwent
simultaneous RFA and resection would be the eﬀectiveness
of the RFA, this group was excluded from the analyses
to prevent any confounding eﬀect. A subgroup analysis
comparing outcomes of patients with solitary metastases
who underwent RFA to those who underwent hepatic
resection was planned a priori.
2.4. Sample Size. It was planned to include all eligible
patients treated during the study period. A sample size
calculation was performed to verify that the sample would
be adequately powered for our primary objective of assessing
local recurrence. It was anticipated that the local recurrence
rate of lesions treated by RFA would be approximately 40%,
while the recurrence rate for lesions treated by resection
would be under 10% [11]. With a P-value of .05, 32 patients
in each group were needed to detect this diﬀerence with a
p o w e ro f. 8 0 .T h en u m b e ro fe l i g i b l ep a t i e n t si ne a c hg r o u p
considerably exceeded this number, so the study was more
than adequately powered to detect this endpoint.
2.5. Statistical Analysis. Overall survival and disease-free
survival were calculated from the date of surgical interven-
tion. Continuous variables were analyzed with Student’s t
test, and categorical variables were analyzed with a chi-
square or Fisher’s Exact Test where appropriate. Survival
and recurrence rates were calculated using the Kaplan-
Meier method and comparisons between groups were doneHPB Surgery 3
Table 1: Overall patient characteristics.
All patients Resection RFA Both P-value (Res versus RFA)∗
n 113 58 43 12
Age Median 67 67 67 63 NS
R a n g e 2 8t o8 3 2 8t o8 3 3 7t o8 3 4 5t o8 2
Gender M 61 29 25 7 NS
F5 2 2 9 1 8 5
Primary site Colon 80 44 29 7 NS
Rectal 33 14 14 5
ASA score Median 2 2 2 2 NS
Range 1 to 3 1 to 3 2 to 3 2 to 3
Timing of primary Synchronous 51 24 21 6 NS
Metachronous 62 34 22 6
Node Pos primary† Yes 69 33 27 9 NS
No 34 20 13 1
No. lesions Median 1 1 2 3.5 NS
Range 1 to 7 1 to 7 1 to 6 1 to 5
Solitary lesion Yes 58 37 19 0 <.001
No 54 20 24 12
Size (cm) Median 4 4.1 3 4.8 .012
Range 1 to 14.5 1.5 to 14.5 1 to 7.5 1.2 to 7
Bilateral disease† Yes 22 2 13 7 <.001
No 31 17 11 5
Preop CEA (mg/L)† Median 18.1 24 18.1 6.1 NS
Range 0 to 699 0 to 279 1 to 699 2 to 58
∗P-value for comparison between patients undergoing resection alone compared to those undergoing RFA alone.
†There are missing values for some patients for the marked variables.
with the logrank test. Predictors of overall and disease-free
survival were analyzed by performing a Cox Proportional
Hazards regression model using a backwards selection
process. A P-value of .05 was used to deﬁne statistical
signiﬁcance.
3. Results
3.1. Patients. During the study period, 58 patients under-
went hepatic resection, 43 underwent RFA, and 12 under-
went simultaneous hepatic resection and RFA for colorectal
liver metastases. Table 1 shows the patient characteristics in
each group. Three patients were lost to follow-up, either
because they lived out of province or moved out of province
during the study period. The mean and median follow-up
duration for all patients was 38 months and 33 months,
respectively. The median follow-up duration for those who
had resection, RFA, and both resection and RFA was 25
months (range 4 to 106), 42 months (range 15 to 85), and
20 months (range 15 to 45), respectively. There were no
signiﬁcant diﬀerences between groups.
3.2. Procedure and Complications. Sixty-eight percent of
patientsinthegroupwhohadliverresectionalonehadmajor
resections (a lobectomy or greater). The operative time was
signiﬁcantly longer for the resection group compared to the
RFAgroup(medianof269minutes(range118to452)versus
204 minutes (range 113 to 316); P < .0005). Operative blood
loss (median 1400mL (range 100 to 9000) versus 150mL
(range 50 to 2300); P < .0005) and transfusion requirements
(44% of patients versus 5%; P < .0005) were higher for
resection than for RFA. Rates of ICU admission (6.5% of
patients overall), and length of stay (median of 7 days for
all patients; range 1 to 48) were not signiﬁcantly diﬀerent
between patients having hepatic resection and RFA. More
patients developed complications with resection compared
to RFA (59% compared to 43%), but the diﬀerence was
not statistically signiﬁcant. Overall, 32% of all complications
weremajor(GradeIIIorhigher),andtherewasnodiﬀerence
between groups. There was only one postoperative death,
which occurred in a patient who underwent RFA alone.
3.3. Overall Survival. The median survival for patients who
had resection, RFA, and resection in combination with
RFA of their CRC metastases was 3.8 years (95% CI =
3.0 to 5.9 years), 2.6 years (95% CI = 1.8 to 3.3 years),
and 2.3 (95% CI = 1 . 6t o3 . 2y e a r s ) ,r e s p e c t i v e l y .T h e5 -
year overall survival after resection alone was 43% (95%
CI = 26 to 58%), while the 5-year survival after RFA
alone was 23% (95% CI = 11 to 39%), as shown in
Figure 1. This diﬀerence was statistically signiﬁcant (P =
.02). When comparing the overall survival in patients who
underwent surgical resection to those who had RFA alone,
thefollowingvariablesweresigniﬁcantonunivariateanalysis4 HPB Surgery
Table 2: Results of univariate analysis of predictors of overall survival.
Med OS (Yr) 5-yr OS (%) Hazard ratio 95% conﬁdence interval P-value
Procedure RFA 2.6 23 1.00
Resection 3.8 43 0.54 0.32 .91 .021
Age <70 3.5 38 1.00
≥70 2.5 26 1.81 1.08 3.05 .025
Gender Male 3.1 30 1.00
Female 3.4 38 0.87 0.51 1.51 .630
Hospital HSC 3.3 30 1.00
SBGH 3.3 40 1.04 0.60 1.78 .900
Primary tumor Colon 3.3 36 1.00
Rectum 2.5 28 1.13 0.63 2.00 .660
Node positive primary No 3.1 44 1.00
Yes 3.3 30 0.97 0.54 1.72 .910
Timing of lesion(s) Synchronous 3.8 50 1.00
Metachronous 2.4 19 1.99 1.17 3.39 .012
Bilateral disease Yes 2.4 36 1.00
No 3.3 32 0.78 0.40 1.57 .460
No. lesions <5 3.3 37 1.00
≥5 2.1 0 2.93 1.30 6.60 .009
Size of lesion(s) <5cm 3.5 44 1.00
≥5cm 2.5 11 1.85 1.09 3.17 .024
Postoperative chemo Yes 3.0 24 1.00
No 3.3 39 0.85 0.49 1.45 .540
(see Table 2): which procedure was performed, age (less than
70 versus 70 or greater), size of metastasis (under 5cm
versus 5cm or greater), number of lesions (less than 5 versus
5 or more), and the timing of the lesion (patients with
synchronouslesionshadbettersurvivalcomparedtopatients
with metachronous disease). In the multivariate analysis,
age was no longer a signiﬁcant predictor of survival. The
other variables remained signiﬁcant (Table 3). The majority
of patients (67%) received postoperative chemotherapy, but
this was not signiﬁcantly associated with increased survival.
Thirty-two patients underwent repeat surgical proce-
dures for recurrent disease in their liver and/or lungs.
Seven patients underwent a subsequent hepatic resection
and 13 patients underwent a subsequent RFA procedure.
Three of the patients who underwent an additional RFA for
recurrence also underwent a pulmonary resection for metas-
tases. Another 12 patients underwent pulmonary resections
without repeat liver procedures.
A preplanned subgroup analysis was performed for
patients with solitary lesions treated by resection versus RFA.
The median overall survival times in this subset for resection
and for RFA were 4.9 years (95% CI = 3.7 to 7.7 years) and
3.0 years (95% CI 1.6 to 3.4 years), respectively. The 5-year
survival rates were 48% (95% CI = 26 to 67%) and 15%
(95% CI = 2.6 to 38%), respectively. The overall survival
for patients with solitary liver lesions treated by resection
comparedtoRFAisshowninFigure 2.Thesizeofthesolitary
lesion (under 5cm versus 5cm or greater) and the procedure
performed were independent predictors of overall survival
(Table 4). Even when limited to solitary lesions less than
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Figure 1: Overall survival.
3cm in diameter, the survival associated with resection was
signiﬁcantly greater than with RFA.
3.4. Disease-Free Survival and Recurrence. The median times
to recurrence for patients who had hepatic resection, RFA,
a n dr e s e c t i o np l u sR F Aw e r e1 1m o n t h s( r a n g e2t o4 9 ) ,
7 months (range 1 to 26), and 8 months (range 2 to
30), respectively. The 5-year disease-free survival (DFS)
for patients who underwent hepatic resection was 17%HPB Surgery 5
Table 3: Results of multivariate Cox Proportional Hazards regres-
sion model of predictors of overall survival.
Hazard
ratio
95% conﬁdence P-value
interval
Procedure
RFA 1.00
Resection 0.36 0.19 0.70 .002
Size of
lesion(s)
<5cm 1.00
≥5cm 2.43 1.26 4.67 .008
No. lesions
<5 1.00
≥5 6.08 2.21 16.70 <.001
Timing of
lesion(s)
Synchronous 1.00
Metachronous 2.92 1.50 5.70 .002
Table 4: Results of multivariate Cox Proportional Hazards regres-
sion model of predictors of overall survival in patient with solitary
liver metastases.
Hazard
ratio
95% conﬁdence P-value
interval
Procedure RFA 1.00
Resection 0.38 0.18 0.81 .013
Size of
lesion(s)
<5cm 1.00
≥5cm 3.06 1.43 6.55 .004
Timing of
Lesion(s)
Synchronous 1.00
Metachronous 3.36 1.39 8.14 .007
(95% CI = 7 to 29%), compared to 15% (95% CI = 6t o
28%) for patients who underwent RFA alone (P =.06). In
a multivariate regression the procedure performed, the size
of lesion, the number of lesions, and the hospital where
the surgery was performed were independent predictors of
disease-free survival.
T h er a t e so fl o c a lr e c u r r e n c ew e r ed r a m a t i c a l l yd i ﬀerent
(Figure 3). Over the course of the study (mean follow-up of
46 months for patients undergoing RFA), 60% of patients
who had only open RFA suﬀered local recurrences compared
to 7% of patients who underwent hepatic resection (P
<.0005). Over the study period, the local recurrence rate
dropped, and in the last 4 years of the study period it was
43%. The local recurrence rate in 10 patients with small
(3cm or smaller), solitary lesions treated by RFA was still
50%.
4. Discussion
This is a population-based study reporting the experience
with RFA and hepatic resection in the Province of Manitoba,
Canada. By accessing provincial vital statistics information
from the Government, the survival ﬁgures in this study are
thought to be quite accurate. The 5-year survival was 43%
0123456789
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Figure 2: Overall survival for patients with solitary metastases.
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Figure 3: Local recurrence rates.
(95% CI = 26% to 58%) and the median survival was 3.8
years (95% CI = 3.0 to 5.9 years) following hepatic resection
in this study. This generally compares favorably to other
reports in the literature [17–19], suggesting that these results
are generalizable. The number of metastases and the size
of metastases were found to be independent predictors of
survival, as seen in other reports [17]. Chemotherapy use
was not standardized in the study, but was not found to be a
predictor of increased survival on univariate or multivariate
analysis.
The unexpectedly high local recurrence rate with RFA is
an alarming ﬁnding. With a median follow-up of 42 months,
patients who underwent RFA alone had a local recurrence
rate of 60%. This is higher than what is reported elsewhere
in the literature and may be due to several causes. Firstly,
the median length of follow-up in this study is longer than
most other reports. Other studies report recurrence rates6 HPB Surgery
from 6% to 39% with follow-up ranging from 6 to 28
months [3, 4, 6, 7, 10, 20–28] .A b d a l l ae ta l .r e p o r t e dal o c a l
recurrencerateof9%afterRFAforcolorectallivermetastases
withafollow-upof21months[10].Whentheyupdatedtheir
experience with a subgroup of patients with solitary lesions
receivingRFA,thelocalrecurrencerateroseto37%whenthe
follow-up had lengthened to a median of 31 months [11].
Perhaps with longer follow-up, the local recurrence rate in
their series may have been even higher.
Another reason for this high local recurrence rate is
that this study represents the initial experience with this
technology in the Province of Manitoba. Part of the high rate
may be due to a learning curve, which seems to be present
over the ﬁrst 40 to 50 cases [14, 29, 30]. Furthermore, the
selection criteria over the time frame of this study changed.
Intheearlyyearsofthestudy,lesionsaslargeas6to7.5cmin
diameter were being ablated. Treatment of such large lesions
is associated with very high recurrence [5, 14, 31]a n dm o s t
centers would restrict RFA to smaller lesions. In fact, there
was a trend to ablation of smaller lesions over the course
of the study, but the trend was not statistically signiﬁcant
(P = .077). Similarly, there was a nonsigniﬁcant trend to
treat lower number of lesions per single patient over time in
the present study, since a high number of lesions are a risk
factor for local recurrence [2]. Both the number and size of
metastases were signiﬁcant predictors of overall survival and
disease-freesurvivalinthemultivariateanalysesinthisstudy.
Patients with lesions over 5cm in size and/or with more than
4 or 5 lesions would generally no longer be treated by RFA
in Manitoba. In addition, many patients were considered to
haveunresectablediseaseduetoproximitytocriticalvascular
structures, which may have acted as a “heat-sink.” A more
aggressive surgical approach has been adopted in the recent
years and it is likely that many such patients would now
undergo resection. It is likely that with more experience and
improvements in selection criteria, the recurrence rates will
fall in the future. Towards the end of the study period, the
local recurrence rate did drop to 43%, which is much closer
to what has been reported from other larger centers [11, 32].
This is likely due to more prudent patient selection, although
the shorter follow-up for these later patients may also play a
role.
There are other reports of very high local recurrence
following RFA of colorectal liver metastases in the recent
literature as well. In one of the largest series, Berber and
Siperstein [32] recently reported a local recurrence rate for
colorectal lesions of 34% with a median of 12 months of
follow-up. Other reports suggest the recurrence rate may be
close to 40% [5, 6, 11]. Therefore, while a local recurrence
rate of 60% seems inappropriately high, the changes in
patient selection and techniques that have evolved are not
expected to reduce recurrence to the range seen following
hepatic resection.
R F Aw a sa s s o c i a t e dw i t hw o r s es u r v i v a la n dr e c u r r e n c e
compared to hepatic resection in all analyses in this study.
Others have also shown inferior survival with RFA compared
to resection. In a series of 418 patients with colorectal
metastases, Abdalla et al. [10] reported a 4-year survival
following hepatic resection of 65%. This was signiﬁcantly
higher than the 36% 4-year survival following resection
plus RFA and the 22% 4-year survival following RFA
alone.
Some studies have shown more promising results. In a
series of 45 consecutive patients with solitary colorectal liver
metastases Oshowo et al. [8] reported almost identical 3-
year survival following RFA compared to resection (53%
a n d5 5 % ,r e s p . ) .Ar e c e n tr e p o r tf r o mB e r b e ra n dS i p e r s t e i n
[33] described their experience with 158 patients who
underwentlaparoscopicRFAand90patientswhounderwent
open resection of solitary colorectal liver metastases. The
actual 5-year survival was 30% for RFA and 40% for
resection, which was not statistically diﬀerent. However, the
3-year survival for RFA in patients without extrahepatic
disease was 35% compared to 70% for those who had liver
resection.
All patients in the current series and in the other series
listed above who underwent RFA were considered to have
unresectable disease, and consequently there must be some
selection bias present. It is very likely that there were
inherent diﬀerences in the biology and aggressiveness of
the tumors’ behavior between the two groups. Because the
study is retrospective, it is impossible to completely control
for these diﬀerences. In this study patients who underwent
RFA more often had multiple lesions and bilateral lesions.
In addition, RFA is oﬀered more commonly to patients
with multiple medical comorbidities, which may also bias
survival in favor of resection. These fundamental diﬀerences
will always be a limitation in interpreting the results of
such studies that show inferior results with RFA in patients
with unresectable disease compared to hepatic resection in
patientswithresectabledisease.Arandomized trialwithvery
strict inclusion criteria would be needed to eliminate this
weakness [7–9]. However, the high local recurrence rates
following RFA observed in this study and others [10, 11]a r e
diﬃcult to ignore. Even with solitary lesions less than 3cm in
diameter, the recurrence rate with hepatic resection appears
to be superior to that of RFA.
5. Conclusions
With the 0% operative mortality rate for hepatic resection
in this study and the very low mortality reported by others in
theliterature[17,18,34],theimprovedsafetyofliversurgery
is well established. Until current RFA technology improves
or alternative ablation technology is developed with much
improved local recurrence rates, it would be very diﬃcult
to support a randomized trial. The results observed in this
study support the consensus that RFA cannot be considered
an equivalent procedure to hepatic resection. Resection
must be considered the standard of care for colorectal
metastases.
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